Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo — Mounjaro is not licensed for a five-day dosing interval. The medicine is designed as a once-weekly subcutaneous injection, meaning doses are separated by seven days, and shortening that gap is not supported by clinical evidence or the licensed schedule. That said, if a dose is taken slightly early due to a scheduling clash, understanding what that means practically is a fair question to bring to your prescriber. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber must assess your suitability and guide any timing decisions — not a dosing chart found online.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the most common assumption people make, and it deserves a direct correction. The idea that Mounjaro's seven-day interval is a loose guideline (something that can be shortened to five days if it fits the week better) isn't accurate. The entire clinical programme, including the SURMOUNT-1 trial published in the New England Journal of Medicine, was built on a once-weekly injection. The pharmacokinetics of tirzepatide (the active molecule) were designed around that interval: a slow rise to a working level in the bloodstream, a stable period, then a gradual taper before the next dose arrives.
Compress that to five days and you're injecting during a period when the previous dose hasn't finished its work. That doesn't make the medicine work faster. It raises the chance of overlapping side effects (particularly the nausea, stomach discomfort and fatigue that are already most noticeable around dose changes) without any evidence of better weight outcomes. The five-day question is understandable; the answer from the licensed schedule is firm.
If you're curious about a six-day gap instead, that's a closer call, and our page on six-day intervals covers the nuance in detail.
The Mounjaro SmPC, available in full on the Electronic Medicines Compendium, gives clear guidance: once weekly, on the same day each week where possible. If you need to shift injection day (because of travel, a medical procedure, or any other practical reason) doses may be given earlier or later than the usual day, provided a minimum gap of four days (96 hours) is maintained between injections.
That four-day minimum is not an invitation to use a shorter cycle permanently. It's a one-off adjustment mechanism. A five-day interval used consistently week after week is a different matter entirely, it would mean every injection falls inside the adjusted window, and the cumulative effect of that on tolerability and dosing hasn't been studied. The prescribing information doesn't support it as a routine approach.
For those wondering about the outer boundary (what happens if a dose runs a day or two long) our page on eight-day intervals addresses that scenario. Scheduling questions come in both directions.
Timing decisions about a prescription-only medicine are clinical decisions. They depend on which dose you're on, how long you've been on it, how your body has responded, and whether any other medicines or conditions are relevant. Someone on 2.5mg in their first four weeks faces a different picture from someone established on 10mg who wants to shift injection day ahead of a holiday.
At nume, every repeat order is reviewed by a prescriber before it's dispensed, a real clinician reads your notes, not software. If a timing question comes up during that review, it gets answered in context. The pen itself arrives via DPD the next working day in plain, unbranded packaging, but what matters before it reaches you is that a qualified prescriber has looked at the full picture.
If you're weighing up your options more broadly, the Mounjaro treatment overview covers how the medicine works, what the trial results showed, and what the licensed eligibility criteria look like. Questions about BMI thresholds and suitability are answered there too. For a broader look at which weight-loss treatments might fit your situation, that page compares the options side by side.
One more practical note: if the underlying concern is about what happens when you take a dose a day ahead of schedule (not a permanent change, just a one-time shift) this page on taking a dose a day early is the more specific resource. The short version is that the four-day minimum gap applies, and your prescriber or the Patient Information Leaflet should be your guide for anything beyond that. Tirzepatide is the generic name for the same molecule, and the same interval rules apply regardless of which name you search under.
Understanding the cost context is also reasonable before starting any private treatment. The Mounjaro cost page lays out what private pricing covers and what to watch for when comparing providers. For any remaining questions about the process, our FAQs cover the most common ones.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.